# Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose

> **NCT00405808** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 2666 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00405808
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 2666 (ACTUAL)
- **Why stopped:** EMEA recommendation to suspend Acomplia marketing authorisation
- **Last updated:** 2011-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405808, "Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00405808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*